7.0.

Abstract
According to the WHO, glioblastoma are malignant astroglial tumors of grade IV. They are
characterized by rapid growth, cellular polymorphism, creation of necrosis,
neovascularization and the infiltration of neighbouring brain structures. By genetic alterations
glioblastoma can be divided into primary (IDH wild type) and secondary( with IDH mutation)
glioblastoma that are histologically indistinguishable, except by immunohistochemical
expression and molecular diagnostics. Considering the diffuse infiltrative growth in brain
structures, complete resection of the affected part of the brain is not possible which is a
problem during bioptic sampling. Histopathological diagnosis is often conditioned by
glioblastoma sample which is deficient and/or necrotic and that creates a problem in setting
up diagnosis. In this research we have used tissue samples from 32 patients operated on
because of glioblastoma. Immunohistochemical analysis of glioblastoma tissues was made on
32 previously frozen samples and 32 unfrozen samples embedded in paraffin and made by
TMA method. Antibodies were used on GFAP, S100, IDH1 and Ki-67. The research
compared the quality of immunohistochemical reactions on both types of samples. The aim of
the research was focused on comparison of the validity of immunohistochemical reaction on
previously frozen glioblastoma tissues in comparison to unfrozen tissue embedded in paraffin,
so that frozen tissue embedded in paraffin could be used for immunohistochemical staining in
case that amount of subsequently obtained glioblastoma tissues is insufficient or if the
subsequently obtained tissue was necrotic. The results of immunohistochemical analysis show
that there is no significant difference in the quality of immunohistochemical reactions
between both types of sample by comparing each antibody individually as with collective
comparison of all antibodies. The credibility of the results in this study is contributed to:
application of TMA method , the use of validated method of immunohistochemical staining of
tissue and validated antibodies, which reduces technical variability to minimum.